Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality

Kerr, Alastair G; Dodwell, David; McGale, Paul; Holt, Francesca; Duane, Fran; Mannu, Gurdeep; Darby, Sarah C.; Taylor, Carolyn

doi:10.1016/j.ctrv.2022.102375

Cited by 162 publications

(97 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Owing to the development of anti-cancer drugs, numerous studies have reported that preoperative chemotherapy improves the survival rates after surgery and demonstrated the effect of properly administered chemotherapy and performed surgery even when effective treatment was considered impossible [ 25 , 26 , 27 , 28 ]. Nevertheless, no treatment options have been accepted as the standard neoadjuvant or adjuvant setting for HCC [ 29 , 30 , 31 ], and considerable numbers of HCC patients with cancer died; therefore, unmet medical needs have steadily increased.…”

Section: Discussionmentioning

confidence: 99%

Drug Discovery Using Evolutionary Similarities in Chemical Binding to Inhibit Patient-Derived Hepatocellular Carcinoma

Lim

Park²,

Choi

et al. 2022

IJMS

View full text Add to dashboard Cite

Drug resistance causes therapeutic failure in refractory cancer. Cancer drug resistance stems from various factors, such as patient heterogeneity and genetic alterations in somatic cancer cells, including those from identical tissues. Generally, resistance is intrinsic for cancers; however, cancer resistance becomes common owing to an increased drug treatment. Unfortunately, overcoming this issue is not yet possible. The present study aimed to evaluate a clinical approach using candidate compounds 19 and 23, which are sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) inhibitors, discovered using the evolutionary chemical binding similarity method. mRNA sequencing indicated SERCA as the dominant marker of patient-derived anti-cancer drug-resistant hepatocellular carcinoma (HCC), but not of patient-derived anti-cancer drug-sensitive HCC. Candidate compounds 19 and 23 led to significant tumor shrinkage in a tumor xenograft model of anti-cancer drug-resistant patient-derived HCC cells. Our results might be clinically significant for the development of novel combinatorial strategies that selectively and efficiently target highly malignant cells such as drug-resistant and cancer stem-like cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Drug Discovery Using Evolutionary Similarities in Chemical Binding to Inhibit Patient-Derived Hepatocellular Carcinoma

Lim

Park²,

Choi

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…In 2020, female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer with an estimated 2.3 million new cases (11.7%) followed by lung (11.4%) ( Sung et al, 2021 ). Breast cancer is a highly heterogeneous disease that includes multiple intrinsic subtypes with heterogeneous molecular profiles, clinical representations, response to therapies and outcomes ( Kerr et al, 2022 ). Although intensive chemotherapy, radiotherapy and targeted therapies have improved the outcomes of breast cancer patients, it is the fifth leading cause of cancer mortality worldwide, with 685,000 deaths ( Sung et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

DNMT3A and DNMT3B in Breast Tumorigenesis and Potential Therapy

Man

Wang

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Breast cancer has become a leading cause of cancer-related deaths in women worldwide. DNA methylation has been revealed to play an enormously important role in the development and progression of breast cancer. DNA methylation is regulated by DNA methyltransferases (DNMTs), including DNMT1, DNMT2, and DNMT3. DNMT3 family has three members: DNMT3A, DNMT3B, and DNMT3L. The roles and functions of DNMT1 in breast cancer have been well reviewed. In this article, the roles of DNMT3A and DNMT3B in breast tumorigenesis and development are reviewed. We also discuss the SNP and mutations of DNMT3A and DNMT3B in breast cancer. In addition, we summarize how DNMT3A and DNMT3B are regulated by non-coding RNAs and signaling pathways in breast cancer, and targeting the expression levels of DNMT3A and DNMT3B may be a promising therapeutic approach for breast cancer. This review will provide reference for further studies on the biological functions and molecular mechanisms of DNMT3A and DNMT3B in breast cancer.

show abstract

“…Breast cancer, a disease that is still the leading cause of cancer death in women worldwide ( 3 ), is regularly treated with chemotherapeutics. Adjuvant and neoadjuvant therapy options depend on the distinct histological subtype, molecular tumor biology, and clinical stage ( 4 ). Generally, recommended treatment options are chemotherapeutical substances such as anthracycline, taxane, platinum, and capecitabine as well as trastuzumab, pertuzumab, emtansine, and neratinib for antihuman epidermal growth factor receptor 2 therapy ( 4 ).…”

Section: Introductionmentioning

confidence: 99%

“…Adjuvant and neoadjuvant therapy options depend on the distinct histological subtype, molecular tumor biology, and clinical stage ( 4 ). Generally, recommended treatment options are chemotherapeutical substances such as anthracycline, taxane, platinum, and capecitabine as well as trastuzumab, pertuzumab, emtansine, and neratinib for antihuman epidermal growth factor receptor 2 therapy ( 4 ). Standard endocrine therapy includes tamoxifen, aromatase inhibitor, and ovarian ablation or suppression ( 4 ).…”

Section: Introductionmentioning

confidence: 99%

“…Generally, recommended treatment options are chemotherapeutical substances such as anthracycline, taxane, platinum, and capecitabine as well as trastuzumab, pertuzumab, emtansine, and neratinib for antihuman epidermal growth factor receptor 2 therapy ( 4 ). Standard endocrine therapy includes tamoxifen, aromatase inhibitor, and ovarian ablation or suppression ( 4 ). Classifications are based on the expression of the hormone receptor and human epidermal growth factor receptor 2.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Chemotherapy-associated oral microbiome changes in breast cancer patients

et al. 2022

View full text Add to dashboard Cite

Cytotoxic chemotherapy with or without a combination of humanized monoclonal antibodies is regarded as the gold standard of personalized medicine for the treatment of breast cancer patients. Significant medication-related side effects are common accompanying phenomena for these patients, such as oral discomfort, mucositis, or even osteonecrosis of the jaw. In this study, we analyze the saliva samples of 20 breast cancer patients at three time points throughout their chemotherapy: at the baseline prior to treatment initiation (T1), after four-to-six cycles of chemotherapy (T2), and 1 year after the start of the treatment (T3) to investigate and characterize the long-term effects of chemotherapy on the oral microbiome. We aimed to characterize changes in the oral bacterial microbiome based on 16S rRNA gene amplicon analysis during chemotherapeutic treatment, as a potential target to treat common oral side effects occurring during therapy. The chemotherapeutic drugs used in our study for patient treatment were trastuzumab, docetaxel, pertuzumab, epirubicin, and cyclophosphamide. We find a significant increase in the relative abundance of potentially pathogenic taxa like Escherichia/Shigella and non-significant trends in the relative abundance of, for example, Actinomyces ssp. In conclusion, the role of microbiota in the oral side effects of chemotherapeutic treatment needs to be considered and should be analyzed in more detail using larger patient cohorts. Oral side effects in breast cancer patients undergoing chemotherapy are a common burden and should be treated for a better tolerability of the therapy.

show abstract

Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality

Cited by 162 publications

References 54 publications

Drug Discovery Using Evolutionary Similarities in Chemical Binding to Inhibit Patient-Derived Hepatocellular Carcinoma

Drug Discovery Using Evolutionary Similarities in Chemical Binding to Inhibit Patient-Derived Hepatocellular Carcinoma

DNMT3A and DNMT3B in Breast Tumorigenesis and Potential Therapy

Chemotherapy-associated oral microbiome changes in breast cancer patients

Contact Info

Product

Resources

About